Federal Register / Vol. 69, No.

240 / Wednesday, December 15, 2004 / Notices
II. Electronic Access Persons with access to the Internet may obtain the documents at http:// www.fda.gov/cdrh/pmapage.html.
Dated: December 3, 2004. Linda S. Kahan, Deputy Director, Center for Devices and Radiological Health. [FR Doc. 04–27387 Filed 12–14–04; 8:45 am]
BILLING CODE 4160–01–S

75075

DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children; Notice of Meeting In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92–463), notice is hereby given of the following meeting:
Name: Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children (ACHDGDNC). Dates and Times: January 13, 2005, 9 a.m. to 5 p.m. January 14, 2005, 9 a.m. to 5 p.m. Place: Ronald Reagan Building and International Trade Center, 1300 Pennsylvania Avenue, NW., Washington, DC 20004. Status: The meeting will be open to the public with attendance limited to space availability. Purpose: The Advisory Committee provides advice and recommendations concerning the grants and projects authorized under the Heritable Disorders Program and technical information to develop policies and priorities for this program that will enhance the ability of State and local health agencies to provide for newborn and child screening, counseling and health care services for newborns and children having or at risk for heritable disorders. Specifically, the Committee shall advise and guide the Secretary regarding the most appropriate application of universal newborn screening tests, technologies, policies, guidelines and programs for effectively reducing morbidity and mortality in newborns and children having or at risk for heritable disorders. Agenda: The first day will be devoted to presentations on and a discussion of the status of the report from the American College of Medical Genetics; an update of the current status of state specific issues; presentations on the Rare Disease Centers of Excellence funded by the National Institutes of Health and the Regional Genetics; and Newborn Screening Collaboratives funded by the Health Resources and Services Administration. The presentations will be followed on the first and second day with more detailed discussions aimed at formulating the ACHDGDNC issues agenda. Proposed agenda items are subject to change.

Time will be provided each day for public comment. Individuals who wish to provide public comment or who plan to attend the meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the ACHDGDNC Executive Secretary, Michele A. Lloyd-Puryear, M.D., Ph.D. (contact information provided below). Contact Person: Anyone interested in obtaining a roster of members or other relevant information should write or contact Michele A. Lloyd-Puryear, M.D., Ph.D., Maternal and Child Health Bureau, Health Resources and Services Administration, Room 18A–19, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443–1080. Information on the Advisory Committee is available at http://mchb.hrsa.gov/programs/genetics/ committee. Dated: December 8, 2004. Tina M. Cheatham, Director, Division of Policy Review and Coordination. [FR Doc. 04–27388 Filed 12–14–04; 8:45 am]
BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the President’s Cancer Panel. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as amended, because the premature disclosure of information and the discussions would likely to significantly frustrate implementation of recommendations.
Name of Committee: President’s Cancer Panel. Date: January 24–25, 2005. Open: January 24, 2005, 8 a.m. to 4 p.m. Agenda: Translating Research to Reduce Burden of Cancer. Place: Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Closed: January 25, 2005, 9 a.m. to 12 p.m. Agenda: The Panel will supplement its public hearings with discussion of

prepublication manuscripts on Translating Research into Clinical Practice. These manuscripts have been provided by their authors with the understanding that the Panel will not break prepublication embargo conditions. Place: Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Contact Person: Maureen O. Wilson, PhD, Executive Secretary, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A18, Bethesda, MD 20892, 301/496–1148. Any interested person may file written comments with the committee by forwarding the comments to the Contact Person listed on this notice. The comments should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: deainfo.nci.nih.gov/advisory/pcp/pcp.htm, where an agenda and any additional information for the meeting will be posed when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: December 6, 2004. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 04–27407 Filed 12–14–04; 8:45 am]
BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel

VerDate jul<14>2003

16:24 Dec 14, 2004

Jkt 205001

PO 00000

Frm 00033

Fmt 4703

Sfmt 4703

E:\FR\FM\15DEN1.SGM

15DEN1